25 XP   0   0   10

Antibe Therapeutics Inc.
Buy, Hold or Sell?

Let's analyse Antibe Therapeutics Inc. together

PenkeI guess you are interested in Antibe Therapeutics Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Antibe Therapeutics Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Antibe Therapeutics Inc.

I send you an email if I find something interesting about Antibe Therapeutics Inc..

Quick analysis of Antibe Therapeutics Inc. (30 sec.)










What can you expect buying and holding a share of Antibe Therapeutics Inc.? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$0.49
Expected worth in 1 year
C$0.16
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
C$-0.33
Return On Investment
-111.5%

For what price can you sell your share?

Current Price per Share
C$0.30
Expected price per share
C$0.15 - C$0.35
How sure are you?
50%

1. Valuation of Antibe Therapeutics Inc. (5 min.)




Live pricePrice per Share (EOD)

C$0.30

Intrinsic Value Per Share

C$-2.22 - C$1.56

Total Value Per Share

C$-1.72 - C$2.06

2. Growth of Antibe Therapeutics Inc. (5 min.)




Is Antibe Therapeutics Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$18.9m$36.2m-$12.4m-52.3%

How much money is Antibe Therapeutics Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$3.3m-$3.7m$326.6k9.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Antibe Therapeutics Inc. (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Antibe Therapeutics Inc.? (5 min.)

Welcome investor! Antibe Therapeutics Inc.'s management wants to use your money to grow the business. In return you get a share of Antibe Therapeutics Inc..

What can you expect buying and holding a share of Antibe Therapeutics Inc.?

First you should know what it really means to hold a share of Antibe Therapeutics Inc.. And how you can make/lose money.

Speculation

The Price per Share of Antibe Therapeutics Inc. is C$0.295. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Antibe Therapeutics Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Antibe Therapeutics Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$0.49. Based on the TTM, the Book Value Change Per Share is C$-0.08 per quarter. Based on the YOY, the Book Value Change Per Share is C$-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Antibe Therapeutics Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps-0.06-19.8%-0.06-21.8%-0.07-24.8%-0.08-25.7%-0.05-15.9%
Usd Book Value Change Per Share-0.05-17.7%-0.06-20.3%-0.06-21.1%0.014.8%0.012.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-17.7%-0.06-20.3%-0.06-21.1%0.014.8%0.012.9%
Usd Price Per Share0.68-0.45-0.45-0.82-0.51-
Price to Earnings Ratio-2.91--1.87--1.55--2.58--5.93-
Price-to-Total Gains Ratio-12.98--8.19--7.33--5.86--12.13-
Price to Book Ratio1.89-1.06-0.65-2.48-11.81-
Price-to-Total Gains Ratio-12.98--8.19--7.33--5.86--12.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.215232
Number of shares4646
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.01
Usd Total Gains Per Share-0.060.01
Gains per Quarter (4646 shares)-278.7965.13
Gains per Year (4646 shares)-1,115.16260.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1115-11250261251
20-2230-22400521512
30-3345-33550782773
40-4461-4470010421034
50-5576-5585013031295
60-6691-6700015631556
70-7806-7815018241817
80-8921-8930020842078
90-10036-10045023452339
100-11152-11160026052600

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.044.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%12.028.00.030.0%14.030.00.031.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%12.028.00.030.0%14.030.00.031.8%

Fundamentals of Antibe Therapeutics Inc.

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Fundamental data was last updated by Penke on 2024-04-09 13:21:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Antibe Therapeutics Inc..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Antibe Therapeutics Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Antibe Therapeutics Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Antibe Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-117.5%+117.5%
5Y-117.5%10Y-84.6%-32.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM--216.8%+216.8%
YOY--288.3%+288.3%
5Y-117.5%-449.1%+331.6%
10Y-84.6%-605.5%+520.9%
1.1.2. Return on Assets

Shows how efficient Antibe Therapeutics Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Antibe Therapeutics Inc. to the Biotechnology industry mean.
  • -7.5% Return on Assets means that Antibe Therapeutics Inc. generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Antibe Therapeutics Inc.:

  • The MRQ is -7.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.5%TTM-7.4%-0.1%
TTM-7.4%YOY-6.2%-1.1%
TTM-7.4%5Y-15.6%+8.2%
5Y-15.6%10Y-22.4%+6.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.5%-13.3%+5.8%
TTM-7.4%-12.8%+5.4%
YOY-6.2%-11.7%+5.5%
5Y-15.6%-13.9%-1.7%
10Y-22.4%-15.7%-6.7%
1.1.3. Return on Equity

Shows how efficient Antibe Therapeutics Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Antibe Therapeutics Inc. to the Biotechnology industry mean.
  • -16.2% Return on Equity means Antibe Therapeutics Inc. generated $-0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Antibe Therapeutics Inc.:

  • The MRQ is -16.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.2%TTM-14.6%-1.6%
TTM-14.6%YOY-10.2%-4.4%
TTM-14.6%5Y-32.6%+18.0%
5Y-32.6%10Y-43.1%+10.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.2%-16.9%+0.7%
TTM-14.6%-16.1%+1.5%
YOY-10.2%-15.1%+4.9%
5Y-32.6%-19.3%-13.3%
10Y-43.1%-20.2%-22.9%

1.2. Operating Efficiency of Antibe Therapeutics Inc..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Antibe Therapeutics Inc. is operating .

  • Measures how much profit Antibe Therapeutics Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Antibe Therapeutics Inc. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Antibe Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-116.0%+116.0%
5Y-116.0%10Y-82.3%-33.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM--232.5%+232.5%
YOY--298.2%+298.2%
5Y-116.0%-492.1%+376.1%
10Y-82.3%-632.4%+550.1%
1.2.2. Operating Ratio

Measures how efficient Antibe Therapeutics Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Antibe Therapeutics Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.595-1.595
5Y1.59510Y1.366+0.229
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM-3.310-3.310
YOY-3.890-3.890
5Y1.5955.739-4.144
10Y1.3667.876-6.510

1.3. Liquidity of Antibe Therapeutics Inc..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Antibe Therapeutics Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.06 means the company has $10.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Antibe Therapeutics Inc.:

  • The MRQ is 10.055. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.127. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.055TTM11.127-1.071
TTM11.127YOY13.561-2.434
TTM11.1275Y10.326+0.801
5Y10.32610Y6.651+3.675
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.0553.890+6.165
TTM11.1274.173+6.954
YOY13.5615.344+8.217
5Y10.3266.126+4.200
10Y6.6516.448+0.203
1.3.2. Quick Ratio

Measures if Antibe Therapeutics Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Antibe Therapeutics Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 4.86 means the company can pay off $4.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Antibe Therapeutics Inc.:

  • The MRQ is 4.856. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 13.203. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.856TTM13.203-8.347
TTM13.203YOY20.124-6.921
TTM13.2035Y11.507+1.696
5Y11.50710Y6.834+4.673
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8563.514+1.342
TTM13.2033.998+9.205
YOY20.1245.380+14.744
5Y11.5076.105+5.402
10Y6.8346.404+0.430

1.4. Solvency of Antibe Therapeutics Inc..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Antibe Therapeutics Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Antibe Therapeutics Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.54 means that Antibe Therapeutics Inc. assets are financed with 54.0% credit (debt) and the remaining percentage (100% - 54.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Antibe Therapeutics Inc.:

  • The MRQ is 0.540. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.489. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.540TTM0.489+0.051
TTM0.489YOY0.390+0.099
TTM0.4895Y0.423+0.066
5Y0.42310Y0.438-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5400.339+0.201
TTM0.4890.336+0.153
YOY0.3900.271+0.119
5Y0.4230.366+0.057
10Y0.4380.389+0.049
1.4.2. Debt to Equity Ratio

Measures if Antibe Therapeutics Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Antibe Therapeutics Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 117.3% means that company has $1.17 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Antibe Therapeutics Inc.:

  • The MRQ is 1.173. The company is able to pay all its debts with equity. +1
  • The TTM is 0.969. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.173TTM0.969+0.204
TTM0.969YOY0.642+0.327
TTM0.9695Y0.834+0.135
5Y0.83410Y0.904-0.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1730.388+0.785
TTM0.9690.402+0.567
YOY0.6420.335+0.307
5Y0.8340.426+0.408
10Y0.9040.461+0.443

2. Market Valuation of Antibe Therapeutics Inc.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Antibe Therapeutics Inc. generates.

  • Above 15 is considered overpriced but always compare Antibe Therapeutics Inc. to the Biotechnology industry mean.
  • A PE ratio of -2.91 means the investor is paying $-2.91 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Antibe Therapeutics Inc.:

  • The EOD is -0.922. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.906. Based on the earnings, the company is expensive. -2
  • The TTM is -1.867. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.922MRQ-2.906+1.984
MRQ-2.906TTM-1.867-1.039
TTM-1.867YOY-1.548-0.319
TTM-1.8675Y-2.582+0.715
5Y-2.58210Y-5.935+3.352
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.922-2.264+1.342
MRQ-2.906-2.629-0.277
TTM-1.867-2.680+0.813
YOY-1.548-4.145+2.597
5Y-2.582-6.257+3.675
10Y-5.935-6.254+0.319
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Antibe Therapeutics Inc.:

  • The EOD is -1.010. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.185. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.961. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.010MRQ-3.185+2.174
MRQ-3.185TTM-1.961-1.223
TTM-1.961YOY-1.981+0.020
TTM-1.9615Y-2.530+0.568
5Y-2.53010Y-8.457+5.928
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.010-2.973+1.963
MRQ-3.185-3.333+0.148
TTM-1.961-3.553+1.592
YOY-1.981-5.605+3.624
5Y-2.530-8.376+5.846
10Y-8.457-8.865+0.408
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Antibe Therapeutics Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.89 means the investor is paying $1.89 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Antibe Therapeutics Inc.:

  • The EOD is 0.599. Based on the equity, the company is cheap. +2
  • The MRQ is 1.888. Based on the equity, the company is underpriced. +1
  • The TTM is 1.060. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.599MRQ1.888-1.289
MRQ1.888TTM1.060+0.828
TTM1.060YOY0.652+0.408
TTM1.0605Y2.484-1.424
5Y2.48410Y11.814-9.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5991.896-1.297
MRQ1.8882.115-0.227
TTM1.0602.093-1.033
YOY0.6522.884-2.232
5Y2.4843.542-1.058
10Y11.8143.916+7.898
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Antibe Therapeutics Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.072-0.082+15%-0.085+19%0.019-473%0.012-706%
Book Value Per Share--0.4920.620-21%0.944-48%0.646-24%0.356+38%
Current Ratio--10.05511.127-10%13.561-26%10.326-3%6.651+51%
Debt To Asset Ratio--0.5400.489+10%0.390+38%0.423+28%0.438+23%
Debt To Equity Ratio--1.1730.969+21%0.642+83%0.834+41%0.904+30%
Dividend Per Share----0%-0%-0%-0%
Eps---0.080-0.088+10%-0.100+26%-0.104+30%-0.064-19%
Free Cash Flow Per Share---0.073-0.087+19%-0.079+9%-0.058-20%-0.039-46%
Free Cash Flow To Equity Per Share---0.073-0.086+18%-0.080+9%0.020-472%0.011-744%
Gross Profit Margin--1.0001.0000%1.015-1%1.083-8%1.140-12%
Intrinsic Value_10Y_max--1.563--------
Intrinsic Value_10Y_min---2.215--------
Intrinsic Value_1Y_max---0.111--------
Intrinsic Value_1Y_min---0.193--------
Intrinsic Value_3Y_max---0.130--------
Intrinsic Value_3Y_min---0.608--------
Intrinsic Value_5Y_max--0.097--------
Intrinsic Value_5Y_min---1.052--------
Market Cap15536293.000-215%48978847.11032652554.278+50%32652548.000+50%58945750.206-17%47705785.914+3%
Net Profit Margin----0%-0%-1.1750%-0.8460%
Operating Margin----0%-0%-1.1600%-0.8230%
Operating Ratio----0%-0%1.595-100%1.366-100%
Pb Ratio0.599-215%1.8881.060+78%0.652+190%2.484-24%11.814-84%
Pe Ratio-0.922+68%-2.906-1.867-36%-1.548-47%-2.582-11%-5.935+104%
Price Per Share0.295-215%0.9300.620+50%0.620+50%1.119-17%0.697+33%
Price To Free Cash Flow Ratio-1.010+68%-3.185-1.961-38%-1.981-38%-2.530-21%-8.457+166%
Price To Total Gains Ratio-4.119+68%-12.985-8.193-37%-7.333-44%-5.861-55%-12.132-7%
Quick Ratio--4.85613.203-63%20.124-76%11.507-58%6.834-29%
Return On Assets---0.075-0.074-1%-0.062-17%-0.156+109%-0.224+200%
Return On Equity---0.162-0.146-10%-0.102-37%-0.326+101%-0.431+165%
Total Gains Per Share---0.072-0.082+15%-0.085+19%0.019-473%0.012-706%
Usd Book Value--18923635.20023822899.200-21%36281731.200-48%24818648.598-24%13877251.975+36%
Usd Book Value Change Per Share---0.052-0.060+15%-0.062+19%0.014-473%0.009-706%
Usd Book Value Per Share--0.3590.452-21%0.689-48%0.471-24%0.260+38%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.058-0.064+10%-0.073+26%-0.076+30%-0.047-19%
Usd Free Cash Flow---2805312.000-3327523.200+19%-3044438.400+9%-2230623.882-20%-1556137.629-45%
Usd Free Cash Flow Per Share---0.053-0.063+19%-0.058+9%-0.042-20%-0.029-46%
Usd Free Cash Flow To Equity Per Share---0.053-0.063+18%-0.058+9%0.014-472%0.008-744%
Usd Market Cap11335279.373-215%35734966.85123823303.601+50%23823299.021+50%43006819.350-17%34806141.403+3%
Usd Price Per Share0.215-215%0.6790.452+50%0.452+50%0.817-17%0.509+33%
Usd Profit---3073804.800-3384067.200+10%-3710745.600+21%-3966169.513+29%-2521262.103-18%
Usd Revenue----0%-0%911315.489-100%986657.177-100%
Usd Total Gains Per Share---0.052-0.060+15%-0.062+19%0.014-473%0.009-706%
 EOD+3 -5MRQTTM+17 -12YOY+17 -135Y+10 -2210Y+11 -21

3.2. Fundamental Score

Let's check the fundamental score of Antibe Therapeutics Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.922
Price to Book Ratio (EOD)Between0-10.599
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.856
Current Ratio (MRQ)Greater than110.055
Debt to Asset Ratio (MRQ)Less than10.540
Debt to Equity Ratio (MRQ)Less than11.173
Return on Equity (MRQ)Greater than0.15-0.162
Return on Assets (MRQ)Greater than0.05-0.075
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Antibe Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.638
Ma 20Greater thanMa 500.301
Ma 50Greater thanMa 1000.534
Ma 100Greater thanMa 2000.723
OpenGreater thanClose0.295
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets56,362
Total Liabilities30,425
Total Stockholder Equity25,937
 As reported
Total Liabilities 30,425
Total Stockholder Equity+ 25,937
Total Assets = 56,362

Assets

Total Assets56,362
Total Current Assets28,095
Long-term Assets28,267
Total Current Assets
Cash And Cash Equivalents 11,339
Short-term Investments 13,567
Total Current Assets  (as reported)28,095
Total Current Assets  (calculated)24,906
+/- 3,189
Long-term Assets
Long-term Assets  (as reported)28,267
Long-term Assets  (calculated)0
+/- 28,267

Liabilities & Shareholders' Equity

Total Current Liabilities2,794
Long-term Liabilities27,631
Total Stockholder Equity25,937
Total Current Liabilities
Total Current Liabilities  (as reported)2,794
Total Current Liabilities  (calculated)0
+/- 2,794
Long-term Liabilities
Long-term Liabilities  (as reported)27,631
Long-term Liabilities  (calculated)0
+/- 27,631
Total Stockholder Equity
Total Stockholder Equity (as reported)25,937
Total Stockholder Equity (calculated)0
+/- 25,937
Other
Capital Stock141,607
Common Stock Shares Outstanding 52,665
Net Invested Capital 25,937
Net Working Capital 25,301



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-30
> Total Assets 
0
0
0
738
2,035
1,837
1,983
4,352
3,419
2,417
1,241
789
1,539
860
9,928
9,740
10,613
9,807
11,087
10,726
12,973
12,024
10,339
12,491
13,017
12,121
12,264
14,819
12,893
17,406
15,217
13,838
38,828
29,744
24,518
81,741
102,857
95,857
92,466
89,158
83,487
79,170
73,729
70,561
66,837
60,205
56,362
56,36260,20566,83770,56173,72979,17083,48789,15892,46695,857102,85781,74124,51829,74438,82813,83815,21717,40612,89314,81912,26412,12113,01712,49110,33912,02412,97310,72611,0879,80710,6139,7409,9288601,5397891,2412,4173,4194,3521,9831,8372,035738000
   > Total Current Assets 
0
0
0
457
2,035
1,837
1,983
4,352
3,419
2,397
1,199
729
1,523
844
5,973
5,011
5,962
5,201
6,564
6,223
8,562
7,637
6,059
8,311
8,936
7,796
8,036
10,564
8,525
13,265
11,466
11,507
36,635
27,696
22,826
79,103
73,965
68,063
64,672
61,364
55,852
51,535
44,526
41,546
37,777
31,099
28,095
28,09531,09937,77741,54644,52651,53555,85261,36464,67268,06373,96579,10322,82627,69636,63511,50711,46613,2658,52510,5648,0367,7968,9368,3116,0597,6378,5626,2236,5645,2015,9625,0115,9738441,5237291,1992,3973,4194,3521,9831,8372,035457000
       Cash And Cash Equivalents 
0
0
0
194
1,687
1,470
1,499
3,755
3,187
1,995
906
397
1,192
472
1,291
386
1,093
503
1,954
1,502
3,702
2,648
1,398
3,726
4,236
3,163
3,305
5,993
3,963
8,292
6,579
6,182
30,752
22,444
15,400
71,973
66,790
60,482
58,591
34,807
18,545
13,603
10,529
6,755
8,793
4,143
11,339
11,3394,1438,7936,75510,52913,60318,54534,80758,59160,48266,79071,97315,40022,44430,7526,1826,5798,2923,9635,9933,3053,1634,2363,7261,3982,6483,7021,5021,9545031,0933861,2914721,1923979061,9953,1873,7551,4991,4701,687194000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
25
20,000
31,640
31,810
31,826
32,137
25,514
23,733
13,567
13,56723,73325,51432,13731,82631,81031,64020,0002525252525252525252525252525252525252525252525252525252500000000000
       Net Receivables 
0
0
0
217
279
345
352
473
132
277
248
264
254
280
1,328
1,496
1,475
1,331
1,117
1,181
1,245
1,291
1,221
1,267
1,423
1,487
1,393
1,567
1,477
1,470
1,460
1,694
2,278
2,401
3,036
2,584
2,534
1,599
1,061
1,121
603
412
678
740
625
0
0
006257406784126031,1211,0611,5992,5342,5843,0362,4012,2781,6941,4601,4701,4771,5671,3931,4871,4231,2671,2211,2911,2451,1811,1171,3311,4751,4961,328280254264248277132473352345279217000
       Other Current Assets 
0
0
0
46
70
22
131
124
100
126
44
43
53
68
781
730
690
714
755
763
689
743
741
186
109
226
346
175
128
218
222
182
226
237
2,172
2,364
2,224
5,146
4,995
5,436
5,064
5,710
1,493
915
919
0
0
009199151,4935,7105,0645,4364,9955,1462,2242,3642,17223722618222221812817534622610918674174368976375571469073078168534344126100124131227046000
   > Long-term Assets 
0
0
0
281
0
0
0
0
0
20
43
61
15
15
3,954
4,730
4,651
4,606
4,523
4,502
4,411
4,387
4,280
4,180
4,082
4,325
4,228
4,255
4,368
4,141
3,751
2,331
2,193
2,048
1,692
2,638
28,892
0
27,794
27,794
27,635
27,635
29,203
29,015
29,060
29,106
28,267
28,26729,10629,06029,01529,20327,63527,63527,79427,794028,8922,6381,6922,0482,1932,3313,7514,1414,3684,2554,2284,3254,0824,1804,2804,3874,4114,5024,5234,6064,6514,7303,954151561432000000281000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
84
80
79
76
78
75
71
133
113
94
84
78
69
181
480
407
354
303
252
194
351
309
267
0
0
0
0
0
0
0
0
0
0
0000000000267309351194252303354407480181697884941131337175787679808400000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
661
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,2831,2831,2831,2831,2831,2831,2831,2831,2831,2831,2831,2831,2831,2831,2831,28366100000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,111
3,215
3,135
3,055
3,143
3,125
3,039
2,952
2,865
2,780
2,694
2,606
2,519
2,434
2,348
2,194
1,857
1,771
1,685
1,598
928
869
27,165
26,352
26,352
26,352
26,352
26,352
26,352
26,352
26,352
0
0
0026,35226,35226,35226,35226,35226,35226,35226,35227,1658699281,5981,6851,7711,8572,1942,3482,4342,5192,6062,6942,7802,8652,9523,0393,1253,1433,0553,1353,2153,11100000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
257
257
256
256
256
413
1,460
1,460
1,442
1,442
1,442
1,283
1,283
1,283
2,663
2,708
0
0
002,7082,6631,2831,2831,2831,4421,4421,4421,4601,46041325625625625725700000000000000000000000000000
> Total Liabilities 
0
0
0
1,745
1,049
650
939
1,033
505
662
297
452
391
388
4,644
5,033
5,458
5,656
5,887
7,172
7,416
7,214
7,066
4,516
5,145
5,770
6,566
7,378
7,503
8,344
8,283
10,059
8,051
7,083
7,607
31,477
31,128
31,214
31,242
32,325
31,442
32,398
30,466
30,395
32,041
30,496
30,425
30,42530,49632,04130,39530,46632,39831,44232,32531,24231,21431,12831,4777,6077,0838,05110,0598,2838,3447,5037,3786,5665,7705,1454,5167,0667,2147,4167,1725,8875,6565,4585,0334,6443883914522976625051,0339396501,0491,745000
   > Total Current Liabilities 
0
0
0
1,299
603
210
525
1,033
505
662
297
452
391
388
2,749
3,005
3,268
3,297
3,351
3,147
3,403
3,269
5,982
3,432
2,095
1,369
2,130
2,907
4,950
5,851
5,810
7,595
5,596
4,636
5,075
3,741
3,426
3,583
3,611
4,694
3,811
4,767
2,835
2,764
4,410
2,865
2,794
2,7942,8654,4102,7642,8354,7673,8114,6943,6113,5833,4263,7415,0754,6365,5967,5955,8105,8514,9502,9072,1301,3692,0953,4325,9823,2693,4033,1473,3513,2973,2683,0052,7493883914522976625051,0335252106031,299000
       Short-term Debt 
0
0
0
762
0
0
0
0
0
0
0
25
25
25
1,602
1,643
1,337
1,725
1,353
1,152
1,284
1,691
4,247
1,537
25
21
5
25
2,272
2,314
2,328
2,333
96
46
135
133
134
0
0
0
0
0
0
0
0
0
0
000000000013413313546962,3332,3282,3142,27225521251,5374,2471,6911,2841,1521,3531,7251,3371,6431,6022525250000000762000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,143
2,179
2,218
14
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000142,2182,1792,14300000000000000000000000000000
       Accounts payable 
0
0
0
537
0
0
0
474
505
662
297
427
0
0
1,098
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,482
3,978
5,500
4,521
4,940
2,330
3,162
1,602
2,280
2,816
2,279
3,121
2,835
2,764
4,410
0
0
004,4102,7642,8353,1212,2792,8162,2801,6023,1622,3304,9404,5215,5003,9783,4820000000000000001,09800427297662505474000537000
       Other Current Liabilities 
0
0
0
0
603
210
525
334
0
0
0
0
391
388
49
1,362
1,931
1,572
1,998
1,995
2,119
1,578
1,736
1,895
2,095
1,348
2,125
2,907
2,678
3,537
3,482
5,262
5,500
4,590
4,940
1,278
130
1,981
3,611
4,694
3,811
4,767
2,835
0
0
0
0
00002,8354,7673,8114,6943,6111,9811301,2784,9404,5905,5005,2623,4823,5372,6782,9072,1251,3482,0951,8951,7361,5782,1191,9951,9981,5721,9311,3624938839100003345252106030000
   > Long-term Liabilities 
0
0
0
446
446
440
414
0
0
0
0
0
0
0
1,895
2,027
2,190
2,359
2,536
4,025
4,013
3,945
1,084
1,084
3,049
4,400
4,436
4,472
2,553
2,493
2,473
2,464
2,455
2,447
2,532
27,736
27,702
0
27,631
27,631
27,631
27,631
27,631
27,631
27,631
27,631
27,631
27,63127,63127,63127,63127,63127,63127,63127,63127,631027,70227,7362,5322,4472,4552,4642,4732,4932,5534,4724,4364,4003,0491,0841,0843,9454,0134,0252,5362,3592,1902,0271,8950000000414440446446000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
94
74
65
56
48
133
105
71
0
0
0
0
0
0
0
0
0
0
000000000071105133485665749400000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,399
2,399
2,399
2,399
2,399
27,631
27,631
27,631
27,631
27,631
27,631
27,631
27,631
27,631
27,631
0
0
0027,63127,63127,63127,63127,63127,63127,63127,63127,63127,6312,3992,3992,3992,3992,399000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
236
236
236
236
236
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
1,283
0
0
001,2831,2831,2831,2831,2831,2831,2831,2831,2831,283236236236236236000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-1,007
987
1,188
1,044
3,319
2,914
1,755
944
337
1,148
471
5,284
4,708
5,155
4,151
5,200
3,553
5,557
4,810
3,273
7,975
7,873
6,351
5,699
7,441
5,390
9,062
6,934
3,779
30,777
22,661
16,911
50,264
71,729
64,643
61,224
56,833
52,045
46,772
43,263
40,166
34,796
29,709
25,937
25,93729,70934,79640,16643,26346,77252,04556,83361,22464,64371,72950,26416,91122,66130,7773,7796,9349,0625,3907,4415,6996,3517,8737,9753,2734,8105,5573,5535,2004,1515,1554,7085,2844711,1483379441,7552,9143,3191,0441,188987-1,007000
   Common Stock
0
0
0
1,372
3,553
4,228
4,563
7,206
8,238
8,238
8,238
8,238
8,735
8,740
13,306
13,113
13,949
14,004
15,211
15,518
17,506
17,937
17,935
29,507
30,468
30,884
33,533
36,986
37,374
42,290
44,690
49,666
80,208
80,333
81,055
111,574
137,688
137,961
138,066
139,547
139,569
139,671
140,865
141,489
141,581
0
0
00141,581141,489140,865139,671139,569139,547138,066137,961137,688111,57481,05580,33380,20849,66644,69042,29037,37436,98633,53330,88430,46829,50717,93517,93717,50615,51815,21114,00413,94913,11313,3068,7408,7358,2388,2388,2388,2387,2064,5634,2283,5531,372000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5
22
24
24
28
29
24
21
17
2
8
10
5
-5
-15
-33
-28
18
4
18
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000018418-28-33-15-5510821721242928242422-500000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,445
10,761
11,142
11,790
12,476
12,519
14,293
15,943
17,346
18,671
18,038
18,759
19,463
19,077
18,904
19,228
0
0
0019,22818,90419,07719,46318,75918,03818,67117,34615,94314,29312,51912,47611,79011,14210,76110,44500000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
1,515
1,639
1,708
2,179
2,687
2,850
2,967
3,033
3,075
3,767
3,841
4,838
5,179
5,895
5,998
7,693
8,092
9,845
10,358
10,452
5,981
7,574
8,092
8,097
10,791
11,648
15,382
15,050
13,768
15,145
15,813
15,838
24,646
26,296
10,264
28,935
28,302
29,023
29,727
29,341
10,264
10,264
0
0
0010,26410,26429,34129,72729,02328,30228,93510,26426,29624,64615,83815,81315,14513,76815,05015,38211,64810,7918,0978,0927,5745,98110,45210,3589,8458,0927,6935,9985,8955,1794,8383,8413,7673,0753,0332,9672,8502,6872,1791,7081,6391,515000



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-20,546
Operating Income-20,546-20,546
 
Operating Expense (+$)
Research Development11,308
Selling General Administrative9,238
Selling And Marketing Expenses0
Operating Expense20,54620,546
 
Net Interest Income (+$)
Interest Income1,353
Interest Expense-8
Other Finance Cost-0
Net Interest Income1,345
 
Pretax Income (+$)
Operating Income-20,546
Net Interest Income1,345
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-19,291-20,456
EBIT - interestExpense = -20,554
-19,475
-19,467
Interest Expense8
Earnings Before Interest and Taxes (EBIT)-20,546-19,283
Earnings Before Interest and Taxes (EBITDA)-19,283
 
After tax Income (+$)
Income Before Tax-19,291
Tax Provision-0
Net Income From Continuing Ops-19,291-19,291
Net Income-19,475
Net Income Applicable To Common Shares-19,475
 
Non-recurring Events
Discontinued Operations-184
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-90-1,345
 

Technical Analysis of Antibe Therapeutics Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Antibe Therapeutics Inc.. The general trend of Antibe Therapeutics Inc. is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Antibe Therapeutics Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Antibe Therapeutics Inc..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.295 < 0.3 < 0.35.

The bearish price targets are: 0.295 > 0.15.

Tweet this
Antibe Therapeutics Inc. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Antibe Therapeutics Inc.. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Antibe Therapeutics Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Antibe Therapeutics Inc.. The current macd is -0.05953738.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Antibe Therapeutics Inc. price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Antibe Therapeutics Inc.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Antibe Therapeutics Inc. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Antibe Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) ChartAntibe Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Antibe Therapeutics Inc.. The current adx is 33.77.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Antibe Therapeutics Inc. shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Antibe Therapeutics Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Antibe Therapeutics Inc.. The current sar is 0.50458249.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Antibe Therapeutics Inc. Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Antibe Therapeutics Inc.. The current rsi is 35.64. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Antibe Therapeutics Inc. Daily Relative Strength Index (RSI) ChartAntibe Therapeutics Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Antibe Therapeutics Inc.. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Antibe Therapeutics Inc. price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Antibe Therapeutics Inc. Daily Stochastic Oscillator ChartAntibe Therapeutics Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Antibe Therapeutics Inc.. The current cci is -11.45380529.

Antibe Therapeutics Inc. Daily Commodity Channel Index (CCI) ChartAntibe Therapeutics Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Antibe Therapeutics Inc.. The current cmo is -21.33975629.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Antibe Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) ChartAntibe Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Antibe Therapeutics Inc.. The current willr is -55.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Antibe Therapeutics Inc. is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Antibe Therapeutics Inc. Daily Williams %R ChartAntibe Therapeutics Inc. Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Antibe Therapeutics Inc..

Antibe Therapeutics Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Antibe Therapeutics Inc.. The current atr is 0.03117725.

Antibe Therapeutics Inc. Daily Average True Range (ATR) ChartAntibe Therapeutics Inc. Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Antibe Therapeutics Inc.. The current obv is -2,173,917.

Antibe Therapeutics Inc. Daily On-Balance Volume (OBV) ChartAntibe Therapeutics Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Antibe Therapeutics Inc.. The current mfi is 72.49.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Antibe Therapeutics Inc. Daily Money Flow Index (MFI) ChartAntibe Therapeutics Inc. Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Antibe Therapeutics Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Antibe Therapeutics Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Antibe Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.638
Ma 20Greater thanMa 500.301
Ma 50Greater thanMa 1000.534
Ma 100Greater thanMa 2000.723
OpenGreater thanClose0.295
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Antibe Therapeutics Inc. with someone you think should read this too:
  • Are you bullish or bearish on Antibe Therapeutics Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Antibe Therapeutics Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Antibe Therapeutics Inc.

I send you an email if I find something interesting about Antibe Therapeutics Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Antibe Therapeutics Inc..

Receive notifications about Antibe Therapeutics Inc. in your mailbox!